New medication class
Rock inhibitors ( rho-kinase inhibitors) are not fda
approved yet but unique in their approach to specifically target cells in the trabecular mesh work (drain of eye
) to improve aqueous outflow.
They may also manifest neuroprotection, anti inflammatory, and enhancement of optic nerve blood flow effects. Stay tuned to this most fascinating class of medications.